サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1744925

アデノウイルスワクチンの世界市場

Adenovirus Vaccines

出版日
ページ情報
英文 279 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
アデノウイルスワクチンの世界市場
出版日: 2025年06月06日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 279 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

アデノウイルスワクチンの世界市場は2030年までに12億米ドルに達する見込み

2024年に8億8,010万米ドルと推定されるアデノウイルスワクチンの世界市場は、分析期間2024～2030年にCAGR 5.4%で成長し、2030年には12億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである4種ワクチンは、CAGR 4.4%を記録し、分析期間終了時には7億7,780万米ドルに達すると予測されます。7種混合ワクチンの成長率は、分析期間中CAGR 7.3%と推定されます。

米国市場は2億3,980万米ドルと推定、中国はCAGR 8.3％で成長予測

米国のアデノウイルスワクチン市場は、2024年に2億3,980万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 8.3%で推移し、2030年には2億3,910万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.7%と5.3%と予測されています。欧州では、ドイツがCAGR約3.5%で成長すると予測されています。

世界のアデノウイルスワクチン市場- 主要動向と促進要因のまとめ

なぜアデノウイルスワクチンは感染症予防やワクチンプラットフォーム開発において戦略的重要性を増しているのか？

アデノウイルスワクチンは、アデノウイルス感染症に対する標的免疫としての役割と、より広範なワクチン開発における汎用性の高いベクターとしての役割の両方が認識されつつあります。もともとはアデノウイルスの血清型によって引き起こされる呼吸器感染症や眼感染症、特に軍やハイリスク集団における感染症を予防するために開発されたワクチンであったが、その強固な安全性プロファイル、遺伝子操作の容易さ、強力な免疫原性により、戦略的関連性が拡大しています。

アデノウイルスベクターはまた、特にCOVID-19パンデミックの際、新興感染症への対応を加速させるのに役立っていることが証明されています。外来抗原を効率的に宿主細胞に送達するその能力により、アデノウイルスベースのプラットフォームは現代のワクチン学の最前線に位置づけられ、幅広いウイルス病原体に対するワクチンの迅速な開発が可能となっています。

技術革新とベクター工学は、アデノウイルスワクチンの範囲をどのように前進させているのでしょうか？

次世代のアデノウイルスワクチンは、免疫原性を最適化し、既存の免疫の懸念を軽減し、標的抗原の発現を可能にするように設計されています。ChAdOx1（チンパンジー由来）やAd26のような非複製ベクターや複製欠損ベクターは、自然に循環しているヒトアデノウイルスからの干渉を最小限にするために使用されています。ベクターのデザイン、プロモーターの最適化、抗原の安定性の進歩により、有効性が向上し、治療の可能性が広がっています。

製造プラットフォームもまた、懸濁細胞株、無血清培地、モジュール式バイオプロセシングシステムを用いた大規模かつ迅速な製造をサポートするように進化しています。このような能力により、パンデミック時のワクチン展開の迅速化が可能になり、がん、HIV、ジカ熱、結核などの免疫候補へのパイプラインの多様化が促進されています。異種プライムブースト戦略を用いた併用レジメンは、免疫反応の持続性と幅をさらに高めています。

アデノウイルスワクチンプラットフォームの採用を促進している疾患領域と地域市場は？

アデノウイルスが誘発する肺炎や気管支炎を含む呼吸器疾患は、軍関係者、施設入所者、小児などの閉鎖された集団やリスクの高い集団において、依然として重要な焦点となっています。アデノウイルスをベースとするCOVID-19ワクチンの成功により、これらのプラットフォームが集団予防接種キャンペーンにおいて拡張可能であることが実証され、世界の公衆衛生プログラムへのアピールが広がっています。

北米と欧州は、強固な資金、規制当局の支援、専門機関により、プラットフォームの革新と臨床開発の中心であり続けています。特に中国とインドでは、ベクターベースのワクチン製造への投資が進んでいます。また、ラテンアメリカやアフリカでも、世界ヘルスパートナーシップやパンデミック対策イニシアティブを通じて導入が進んでいます。

規制の枠組み、国民の認識、プラットフォームの多様性はどのように市場の成長を形成しているか？

COVID-19における規制当局の承認と緊急時使用許可（EUA）は、アデノウイルスワクチンプラットフォームの世界の検証を加速させ、将来の迅速な承認に向けた基盤を構築しました。しかしながら、ワクチン接種へのためらい、稀な有害事象への懸念、誤った情報などに関連した一般市民の認識に関する課題もあり、信頼と摂取を維持するためには、継続的な教育と透明性のあるコミュニケーションが必要です。

アデノウイルスベクター固有の多用途性は、がん治療用ワクチンや遺伝子治療デリバリーなど、感染症以外の応用を支えています。このような分野横断的な関連性は、研究開発投資を誘致し、商業的パートナーシップを拡大しています。政府やNGOも、パンデミックや生物防衛計画におけるアデノウイルスワクチンのための備蓄や戦略的予備プログラムを支援しています。

アデノウイルスワクチン市場の成長を促進する要因は何ですか？

アデノウイルスワクチン市場は、スケーラブルなベクター技術、証明された免疫原性、そして感染症や免疫腫瘍学のパイプラインにおける適用性の拡大という強みを背景に進展しています。パンデミックへの備え、世界な予防接種インフラ、迅速な対応開発のためのプラットフォーム適応性への関心の高まりが需要を牽引しています。ベクター工学と製造プロセスにおける継続的な技術革新は、多様な臨床応用におけるプラットフォームの価値を強化しています。

今後、アデノウイルス市場がどのように進化していくかは、アデノウイルス技術がいかに効果的に市場競争、規制当局の期待、世界のアクセスの課題を克服できるかにかかっています。公衆衛生システムがより迅速で機動的なワクチン開発戦略を模索する中、アデノウイルスベースのワクチンは、将来即応性のある予防接種プラットフォームの要として台頭する可能性はあるのだろうか。

セグメント

タイプ（4種ワクチン, 7種ワクチン）;アプリケーション（調査,アカデミック,研究所,製薬&バイオテクノロジー）

調査対象企業の例（注目の42社）

  • Altimmune, Inc.
  • AstraZeneca plc
  • Bavarian Nordic A/S
  • Bharat Biotech International Ltd.
  • CanSino Biologics Inc.
  • ChAdOx1 nCoV-19（Oxford University）
  • Daiichi Sankyo Co., Ltd.
  • Emergent BioSolutions Inc.
  • Gamaleya Research Institute
  • GeneOne Life Science Inc.
  • GlaxoSmithKline plc
  • ImmunityBio, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Medigen Vaccine Biologics Corp.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • ReiThera Srl

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP34546

Global Adenovirus Vaccines Market to Reach US$1.2 Billion by 2030

The global market for Adenovirus Vaccines estimated at US$880.1 Million in the year 2024, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2024-2030. Type 4 Vaccine, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$777.8 Million by the end of the analysis period. Growth in the Type 7 Vaccine segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$239.8 Million While China is Forecast to Grow at 8.3% CAGR

The Adenovirus Vaccines market in the U.S. is estimated at US$239.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$239.1 Million by the year 2030 trailing a CAGR of 8.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Adenovirus Vaccines Market - Key Trends & Drivers Summarized

Why Are Adenovirus Vaccines Gaining Strategic Importance in Infectious Disease Prevention and Vaccine Platform Development?

Adenovirus vaccines are increasingly recognized for their dual role as both targeted immunizations against adenoviral infections and as versatile vectors in the broader vaccine development landscape. Originally developed to prevent respiratory and ocular infections caused by adenovirus serotypes-especially in military and high-risk populations-these vaccines have expanded in strategic relevance due to their robust safety profile, ease of genetic manipulation, and strong immunogenicity.

Adenoviral vectors have also proven instrumental in accelerating responses to emerging infectious diseases, notably during the COVID-19 pandemic. Their ability to deliver foreign antigens effectively into host cells has positioned adenovirus-based platforms at the forefront of modern vaccinology, enabling the rapid development of vaccines against a wide array of viral pathogens.

How Are Technological Innovations and Vector Engineering Advancing the Scope of Adenovirus Vaccines?

Next-generation adenovirus vaccines are being engineered to optimize immunogenicity, reduce pre-existing immunity concerns, and enable targeted antigen expression. Non-replicating and replication-deficient vectors, such as ChAdOx1 (chimpanzee-derived) and Ad26, are being used to minimize interference from naturally circulating human adenoviruses. Advances in vector design, promoter optimization, and antigen stability are enhancing efficacy and expanding therapeutic potential.

Manufacturing platforms are also evolving to support large-scale, rapid production using suspension cell lines, serum-free media, and modular bioprocessing systems. These capabilities are enabling accelerated vaccine rollout during pandemics and facilitating pipeline diversification into oncology, HIV, Zika, and tuberculosis immunization candidates. Combination regimens using heterologous prime-boost strategies are further enhancing immune response durability and breadth.

Which Disease Areas and Geographic Markets Are Driving Adoption of Adenovirus Vaccine Platforms?

Respiratory diseases, including adenovirus-induced pneumonia and bronchitis, remain a key focus in closed or high-risk populations such as military personnel, institutionalized patients, and children. The success of adenovirus-based COVID-19 vaccines has demonstrated the scalability of these platforms in mass immunization campaigns, broadening their appeal to global public health programs.

North America and Europe remain central to platform innovation and clinical development, with robust funding, regulatory support, and institutional expertise. Asia-Pacific is emerging as a key manufacturing and deployment region, particularly in China and India, which are investing in vector-based vaccine capabilities. Adoption is also increasing in Latin America and Africa through global health partnerships and pandemic preparedness initiatives.

How Are Regulatory Frameworks, Public Perception, and Platform Versatility Shaping Market Growth?

Regulatory approvals and Emergency Use Authorizations (EUAs) during COVID-19 have accelerated the global validation of adenoviral vaccine platforms, creating a foundation for faster future approvals. However, public perception challenges-linked to vaccine hesitancy, concerns about rare adverse events, and misinformation-require ongoing education and transparent communication to maintain trust and uptake.

The inherent versatility of adenovirus vectors is supporting applications beyond infectious disease, including therapeutic vaccines for cancer and gene therapy delivery. This cross-sector relevance is attracting R&D investments and expanding commercial partnerships. Governments and NGOs are also supporting stockpiling and strategic reserve programs for adenovirus vaccines in pandemic and biodefense planning.

What Are the Factors Driving Growth in the Adenovirus Vaccines Market?

The adenovirus vaccines market is advancing on the strength of scalable vector technology, proven immunogenicity, and growing applicability across infectious disease and immuno-oncology pipelines. Demand is driven by increasing attention to pandemic preparedness, global immunization infrastructure, and platform adaptability for rapid response development. Ongoing innovation in vector engineering and manufacturing processes is reinforcing the platform's value in diversified clinical applications.

Looking ahead, the market’s evolution will depend on how effectively adenoviral technologies navigate competitive vaccine platforms, regulatory expectations, and global access challenges. As public health systems seek faster, more agile vaccine development strategies, could adenovirus-based vaccines emerge as the cornerstone of future-ready immunization platforms?

SCOPE OF STUDY:

The report analyzes the Adenovirus Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Type 4 Vaccine, Type 7 Vaccine); Application (Research, Academic, Laboratories, Pharmaceutical & Biotechnology)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Altimmune, Inc.
  • AstraZeneca plc
  • Bavarian Nordic A/S
  • Bharat Biotech International Ltd.
  • CanSino Biologics Inc.
  • ChAdOx1 nCoV-19 (Oxford University)
  • Daiichi Sankyo Co., Ltd.
  • Emergent BioSolutions Inc.
  • Gamaleya Research Institute
  • GeneOne Life Science Inc.
  • GlaxoSmithKline plc
  • ImmunityBio, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Medigen Vaccine Biologics Corp.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • ReiThera Srl

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Adenovirus Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Prevalence of Respiratory and Gastrointestinal Infections Throws the Spotlight on Adenovirus Vaccine Demand
    • Expanded Use in Military and Institutional Settings Spurs Routine Adenovirus Immunization
    • Development of Adenoviral Vectors for Emerging Diseases Strengthens the Business Case for Platform Innovation
    • Global Focus on Pandemic Preparedness Drives R&D in Adenovirus-Based Vaccine Technologies
    • Success of Viral Vector COVID-19 Vaccines Bodes Well for Broader Acceptance of Adenovirus Platforms
    • Increasing Pediatric Immunization Campaigns Across Developing Economies Propels Vaccine Deployment
    • Growing Pipeline of Oncology and Gene Therapy Applications Expands Use of Adenovirus as a Delivery Vehicle
    • Expanding Clinical Trials in Rare and Infectious Diseases Generate New Application Frontiers
    • Rising Emphasis on Single-Dose and Needle-Free Delivery Options Enhances Vaccine Adoption Potential
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Adenovirus Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Adenovirus Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Adenovirus Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Adenovirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Type 4 Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Type 4 Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Type 4 Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Type 7 Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Type 7 Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Type 7 Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Academic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Academic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Academic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharmaceutical & Biotechnology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pharmaceutical & Biotechnology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Pharmaceutical & Biotechnology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Adenovirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • JAPAN
    • Adenovirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • CHINA
    • Adenovirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • EUROPE
    • Adenovirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Adenovirus Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Adenovirus Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Adenovirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • FRANCE
    • Adenovirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • GERMANY
    • Adenovirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Adenovirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Adenovirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Adenovirus Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Adenovirus Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Adenovirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Adenovirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • INDIA
    • Adenovirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Adenovirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Adenovirus Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Adenovirus Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Adenovirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Adenovirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Adenovirus Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Adenovirus Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Adenovirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030
  • AFRICA
    • Adenovirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Adenovirus Vaccines by Type - Type 4 Vaccine and Type 7 Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Adenovirus Vaccines by Type - Percentage Breakdown of Value Sales for Type 4 Vaccine and Type 7 Vaccine for the Years 2015, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Adenovirus Vaccines by Application - Research, Academic, Laboratories and Pharmaceutical & Biotechnology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Adenovirus Vaccines by Application - Percentage Breakdown of Value Sales for Research, Academic, Laboratories and Pharmaceutical & Biotechnology for the Years 2015, 2025 & 2030

IV. COMPETITION